–
In the email Landa attempts to rally major shareholders (US funds with major Teva holdings) to lead a campaign for the reduction of the number of directors on Teva’s board from 16 to 12 with more experienced directors in global pharmaceuticals. He also wants to change the company’s constitution so that a lower majority than the current 85% is required to change directors.
In the email he wrote, “I don’t know if this board is able to attract a world class CEO to lead Teva, but with higher standards of corporate governance and a pharma-seasoned board of directors, at least the new CEO will stand a better chance than his predecessor!”
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
He also said that he had spoken with incoming deputy chairman Amir Elstein and that there had been a “meeting of minds” and that the former Israel Corporation (TASE: ILCO) chairman had promised to push forward with the changes asked for by Landa this month.
Teva said, “There have been no talks with institutional investors on behalf of the company’s board of directors.”
Landa declined to comment to the “Financial Times” on his initiative. He also wrote in his email, ” “I am greatly relieved that Teva’s board appears ready to make these bold moves, which, hopefully, will restore investor confidence not only in Teva but also in Israel.”
Landa pioneered digital printing through Indigo which he sold to HP for $830 million in 2003. He is now pioneering nanotechnology printing through Landa Nanographic Printing Ltd.
Published by www.globes-online.com
